Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021 - Seite 3

Results from a Phase 1 trial evaluating VIR-3434 in 40 virally suppressed patients with chronic HBV infection who were randomized to receive a single low dose of either 6 mg or 18 mg for four weeks demonstrate:

• Treatment with VIR-3434 resulted in rapid >1 log₁₀ IU/mL reductions in HBsAg, with the largest reductions (>1.5 log₁₀ IU/mL) observed in the 18 mg cohort; maximum reductions were generally observed within one week.
  
• No new safety signals were identified with single doses of VIR-3434; all adverse events were grade 1 or 2.
  
• No significant changes in liver-related laboratory parameters or clinically significant changes in ALT or other liver-related laboratory parameters were reported.
  
  Oral Presentation: Kosh Agarwal, M.D., consultant hepatologist and transplant physician at the Institute of Liver Studies, King’s College Hospital NHS Foundation Trust in London (Abstract #211).

In a separate Phase 1 trial in 40 healthy adult volunteers evaluating single doses of up to 3,000 mg of VIR-3434 administered subcutaneously or intravenously, results demonstrate:

• Subcutaneous administration of VIR-3434 showed favorable pharmacokinetic properties, with VIR-3434 remaining in the serum for 24 weeks.
  
• No new safety signals were identified; specifically, no grade 3/4 adverse events, serious adverse events or adverse events leading to trial discontinuation were reported.
  
  Poster Presentation: Sneha Gupta, Ph.D., associate director of clinical pharmacology at Vir Biotechnology (Abstract #43).

Conference Call and Webcast Details
Management will host a conference call and webcast featuring Professor Yuen at 11:00 a.m. ET today, June 25, 2021, to discuss the new data presented at the International Liver Congress 2021.

To access the call via telephone, please dial [phone] (North America) or [phone] (International), conference ID: 5476112.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.

The Company has used, and intends to continue to use, the Investors page of its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investors website, in addition to following the Company’s press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.